In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alnylam Pharmaceuticals Inc.

http://www.alnylam.com

Latest From Alnylam Pharmaceuticals Inc.

Alnylam Hopes For Strong hATTR Uptake For Vutrisiran With Longer Data

The company presented 18-month data at a conference that it thinks will support strong uptake. European regulators required the 18-month data for filing; an FDA decision based on 9-month data is expected in April.

J.P. Morgan Day 1: Pharma Execs Offer Big Talk Instead Of Big Deals

Daily notebook from the virtual J.P. Morgan Healthcare Conference: business development is top of mind for BMS, Merck, J&J and Pfizer, while Novartis, Moderna and Regeneron talk about next steps. Bayer looks to minimize Xarelto patent expiry, a new chief exec debuts for Alnylam and EY suggests 2022 will be another year of bolt-on deals. 

BioPharmaceutical

J.P. Morgan Day 1: Pharma Execs Offer Big Talk Instead Of Big Deals

Daily notebook from the virtual J.P. Morgan Healthcare Conference: business development is top of mind for BMS, Merck, J&J and Pfizer, while Novartis, Moderna and Regeneron talk about next steps. Bayer looks to minimize Xarelto patent expiry, a new chief exec debuts for Alnylam and EY suggests 2022 will be another year of bolt-on deals. 

BioPharmaceutical Commercial

AstraZeneca Doubles Down On Amyloidosis With Neurimmune Alliance

The UK major is paying $30m upfront and up to an extra $730m for the rights to Neurimmune’s NI006, which is in Phase Ib trials for the treatment of transthyretin amyloid cardiomyopathy.

Rare Diseases Deals
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
    • Synthesis Technologies, Production Processes
  • Other Names / Subsidiaries
    • Regulus Therapeutics, Inc.
    • Sirna Therapeutics, Inc. Alnylam U.S., Inc Ribopharma AG
UsernamePublicRestriction

Register